ProfileGDS5678 / 1441565_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 52% 51% 50% 51% 54% 52% 49% 53% 52% 64% 58% 59% 53% 53% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3136352
GSM967853U87-EV human glioblastoma xenograft - Control 23.2331451
GSM967854U87-EV human glioblastoma xenograft - Control 33.2133350
GSM967855U87-EV human glioblastoma xenograft - Control 43.1867151
GSM967856U87-EV human glioblastoma xenograft - Control 53.2853454
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3750552
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2567649
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.302753
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2338152
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8115264
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5003758
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5062159
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3030453
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2965853